Polycythemia Vera - Symptoms, Causes, Treatment & Prevention

```html

Overview

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm—a type of blood cancer—in which the bone marrow produces too many red blood cells, and often an excess of white blood cells and platelets. The overproduction thickens the blood, increasing the risk of clotting, bleeding, and organ damage.

• Who it affects: Primarily adults aged 50–70, but it can occur at any age. Men and women are affected almost equally, though a slight male predominance is reported.
• Prevalence: Approximately 1–3 cases per 100,000 people worldwide (Mayo Clinic, 2023). In the United States, about 150,000 people live with PV.

PV is a lifelong condition; however, with modern therapy most patients enjoy a normal or near‑normal life expectancy.

Symptoms

Symptoms develop gradually and can be vague, which often delays diagnosis. Below is a comprehensive list with brief explanations.

General/Constitutional

• Fatigue & weakness: Thickened blood reduces oxygen delivery efficiency.
• Headache or dizziness: Result of increased blood volume and viscosity.
• Night sweats & fever: Common in many myeloproliferative disorders.
• Unexplained weight loss: May signal disease activity.

Skin & Vascular

• Facial plethora (redness): Classic “ruddy” complexion, especially on the cheeks and nose.
• Itching (pruritus), especially after a hot shower: Histamine release triggered by increased mast cell activity.
• Red or bluish lips and tongue.
• Bleeding gums or easy bruising: Platelet dysfunction despite high platelet counts.

Thrombotic (Clot‑Related) Symptoms

• Leg swelling or pain (deep‑vein thrombosis, DVT).
• Chest pain, shortness of breath, or sudden cough with blood (pulmonary embolism).
• Sudden weakness, numbness, slurred speech (stroke).
• Abdominal pain after meals (mesenteric ischemia).

Spleen‑Related

• Fullness or pain in the left upper abdomen: The spleen often enlarges (splenomegaly) as it works harder to filter excess cells.

Other Possible Manifestations

• Gout attacks: Elevated uric acid from increased cell turnover.
• Irregular menstrual periods or erectile dysfunction: Vascular effects can affect reproductive organs.

Causes and Risk Factors

PV is not caused by lifestyle choices; it is a clonal disorder of hematopoietic stem cells.

Primary cause

• JAK2 V617F mutation: Found in >95 % of PV patients. The mutation activates the Janus kinase‑2 pathway, driving uncontrolled blood cell production (NIH, 2022).
• Other JAK2 exon 12 mutations: Present in a minority of JAK2‑negative cases.

Risk factors

• Age ≥ 60 years (risk rises sharply after 50).
• Male sex – modestly higher incidence.
• Family history of myeloproliferative neoplasms (rare hereditary predisposition).
• Exposure to ionizing radiation or certain chemotherapy agents (increase risk for secondary myeloproliferative disorders).

Diagnosis

Diagnosing PV requires a combination of clinical, laboratory, and genetic criteria. The 2016 WHO criteria are most commonly used.

Step‑by‑step diagnostic approach

1. Complete blood count (CBC): Elevated hemoglobin >16.5 g/dL in men or >16.0 g/dL in women, hematocrit >49 % (men) or >48 % (women), and often increased platelet count.
2. Red cell mass measurement (optional): Radioactive chromium or carbon monoxide re‑breathing test confirms true erythrocytosis.
3. Serum erythropoietin (EPO) level: Typically low or suppressed in PV.
4. Bone marrow biopsy: Hypercellular marrow with pan‑myelosis (increased red cells, white cells, and megakaryocytes).
5. JAK2 mutation testing: PCR or sequencing for V617F and exon 12 mutations.
6. Exclusion of secondary causes: Rule out chronic lung disease, high‑altitude residence, obstructive sleep apnea, nicotine use, or dehydration.

Key reference: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. (2022).

Treatment Options

Therapy aims to reduce blood viscosity, prevent thrombosis, control symptoms, and limit disease progression.

1. Phlebotomy (Therapeutic Venesection)

• First‑line for most patients.
• Goal: keep hematocrit <45 % (men) or <42 % (women).
• Typically 500 mL removed weekly until target achieved, then spaced out.

2. Low‑dose Aspirin

• 75–100 mg daily reduces platelet aggregation.
• Contraindicated if platelet count <100 ×10⁹/L or active bleeding.

3. Cytoreductive (Myelosuppressive) Therapy

Indicated for high‑risk patients (age > 60 y or history of thrombosis) and those who cannot maintain target hematocrit with phlebotomy alone.

Medication	Mechanism	Typical Dose	Key Side Effects
Hydroxyurea	Inhibits ribonucleotide reductase → ↓ DNA synthesis	Start 15 mg/kg/day; adjust to keep Hct target	Myelosuppression, leg ulcers, mucocutaneous ulcers, possible leukemogenic risk
Interferon‑alpha (Pegylated)	Modulates immune response; reduces JAK2‑mutated clone	45–90 µg weekly subcutaneously	Flu‑like symptoms, depression, liver enzyme elevation
Ruxolitinib	JAK1/2 inhibitor; decreases cytokine drive	10 mg BID, titrated to blood counts	Infection risk, anemia, thrombocytopenia, weight gain

4. Management of Specific Complications

• Pruritus: Antihistamines, selective serotonin reuptake inhibitors, or short courses of low‑dose steroids.
• Gout: Allopurinol or febuxostat; maintain hydration.
• Splenomegaly causing discomfort: Cytoreductive agents often reduce spleen size; in rare cases, splenectomy is considered.

5. Lifestyle & Supportive Measures

• Stay well‑hydrated (≥2 L water/day).
• Avoid smoking and high‑altitude exposure.
• Maintain a healthy weight and regular aerobic activity (e.g., brisk walking 30 min most days).
• Use compression stockings if prone to leg swelling or DVT.

Living with Polycythemia Vera

Adapting daily life can help control symptoms and reduce complications.

Monitoring

• CBC with differential every 3–6 months (more often when adjusting therapy).
• Blood pressure and cardiovascular risk assessment at each visit.
• Self‑monitor for new headaches, vision changes, calf pain, or chest discomfort.

Practical Tips

• Schedule phlebotomy appointments early in the week to avoid weekend dehydration.
• Keep a symptom diary (pruritus intensity, headaches, bruising) to discuss with your hematologist.
• Wear a medical alert bracelet indicating “Polycythemia vera – on anticoagulant/antiplatelet therapy.”
• Plan travel: stay hydrated, move frequently on long flights, and carry a copy of recent labs.

Psychosocial Support

Living with a chronic blood disorder can be anxiety‑provoking. Consider:

• Joining support groups (e.g., MPN Voice, American Cancer Society forums).
• Speaking with a mental‑health professional if you experience depression or chronic stress.

Prevention

Because PV stems from a genetic mutation, primary prevention is limited. However, you can reduce the risk of complications:

• Control cardiovascular risk factors—blood pressure, cholesterol, diabetes.
• Never smoke; avoid second‑hand smoke.
• Maintain adequate hydration.
• Promptly treat infections to lower inflammatory triggers that may exacerbate clot risk.

Complications

If untreated or poorly controlled, PV can lead to serious health problems.

• Thrombotic events: DVT, pulmonary embolism, myocardial infarction, ischemic stroke (overall 2–3 % per year).
• Hemorrhagic events: Gastrointestinal bleeding or intracranial hemorrhage due to platelet dysfunction.
• Progression to myelofibrosis: Approximately 10–15 % develop secondary myelofibrosis after 10–15 years.
• Transformation to acute leukemia: Rare (<5 %); risk is higher with long‑term hydroxyurea exposure.
• Secondary solid tumors: Slightly increased risk for skin and gastrointestinal cancers; regular screening is advised.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Polycythemia vera.” 2023; Centers for Disease Control and Prevention. “Myeloproliferative neoplasms.” 2022; National Institutes of Health. “JAK2 mutation in myeloproliferative disorders.” 2022; World Health Organization. “Haematolymphoid Tumours – WHO Classification.” 2022; Cleveland Clinic. “Treatment of polycythemia vera.” 2024; Peer‑reviewed articles in Blood and Leukemia journals (2021‑2023).

```